Cognition Therapeutics Files 8-K on Financials

Ticker: CGTX · Form: 8-K · Filed: Mar 20, 2025 · CIK: 1455365

Cognition Therapeutics INC 8-K Filing Summary
FieldDetail
CompanyCognition Therapeutics INC (CGTX)
Form Type8-K
Filed DateMar 20, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, results-of-operations, filing

TL;DR

Cognition Therapeutics dropped an 8-K detailing its financial condition and results.

AI Summary

Cognition Therapeutics, Inc. filed an 8-K on March 20, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Purchase, NY.

Why It Matters

This filing provides crucial updates on Cognition Therapeutics' financial health and operational performance, which are key indicators for investors and stakeholders.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Cognition Therapeutics, Inc.'s Results of Operations and Financial Condition, as well as to include Financial Statements and Exhibits.

When was this 8-K filing submitted?

This 8-K filing was submitted on March 20, 2025.

Where are Cognition Therapeutics, Inc.'s principal executive offices located?

Cognition Therapeutics, Inc.'s principal executive offices are located at 2500 Westchester Avenue, Purchase, NY 10577.

In which state was Cognition Therapeutics, Inc. incorporated?

Cognition Therapeutics, Inc. was incorporated in Delaware.

What is the Commission File Number for Cognition Therapeutics, Inc.?

The Commission File Number for Cognition Therapeutics, Inc. is 001-40886.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 20, 2025 regarding COGNITION THERAPEUTICS INC (CGTX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing